DATAGUARD
5.6.2024 17:29:34 CEST | Business Wire | Press release
DataGuard, a leading Software-as-a-Service (SaaS) company for security and compliance, announced today that it has acquired DPOrganizer. This acquisition expands DataGuard’s footprint particularly in the Nordic region and the UK, and strengthens the company’s market position across its core geographies Europe and North America. DataGuard helps over 4,000 customers active in more than 50 countries build robust security and compliance management systems. Companies use DataGuard’s software platform to get certified and become compliant with frameworks (such as GDPR, CCPA, ISO 27001, NIS 2, or SOC 2) as well as manage their most important risks efficiently, thereby staying ahead of evolving business and regulatory needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240605633259/en/
Security & Compliance Management Software (Photo: Business Wire)
DPOrganizer, a Stockholm-based privacy management solution for privacy professionals and in-house data protection and compliance teams, helps small and large customers in more than 20 countries build and run effective privacy programs, comply with regulation, and build trust with their customers and partners. DPOrganizer’s powerful software toolkit offers incidents and breach management, data subject request handling, data protection impact assessments, and more functionalities. Thanks to the advanced data mapping, analytics and data flow visualization capabilities, data protection officers and privacy professionals can ensure collection and retention of data in line with regulation and best practice, identifying patterns and anomalies, and preventing breaches or non-compliance.
"Today’s announcement is a major milestone on DataGuard’s growth journey. Integrating DPOrganizer’s capabilities will enhance our offering for customers. It helps us build a unique system-of-record for the security and compliance domain that lets companies go beyond certifications and tick-the-box exercises,” says Thomas Regier, co-founder and co-CEO at DataGuard. “This and our comprehensive risk-first approach give DataGuard an asymmetric advantage as we transition into the era of AI-piloted security and compliance programs. We will continue to integrate strategic tech partners natively into our software ecosystem – to further broaden our customer value proposition and expand our geographic footprint.”
“In the era of data and artificial intelligence, organisations are constantly exposed to an increasing number of cyber threats and are required to comply with a multitude of frameworks to continue their business operations. As we know from our customers, ‘the risk is real’, and we believe the best way to address this is to have an effective digital information security and compliance management system. Partnering with DPOrganizer helps us further this mission,” said Kivanc Semen, co-founder and co-CEO at DataGuard.
“DPOrganizer was built for and is loved by privacy and compliance professionals. By joining forces with DataGuard, we can add capabilities such as the AI copilot, asset management, risk and controls management, and numerous information security frameworks. We thereby enable customers to build the bridge between security and compliance, expert and non-expert, business and compliance people. I am beyond excited to start this joint journey and combine our deep domain expertise and technological capabilities. We will continue to give thousands of customers a best-in-class experience,” Egil Bergenlind, co-founder of DPOrganizer summarizes.
About DataGuard
DataGuard is a security and compliance software company trusted by more than 4,000 organisations across the globe. Customers use the platform to build up a scalable risk management and a strong security posture while getting certified fast and complying effortlessly with industry regulation and frameworks such as ISO 27001, TISAX®, NIS2, SOC2, GDPR, and the EU Whistleblower Directive. Our purpose-built software suite offers AI-powered workflow automation and seamless integration capabilities, reducing the time and money organisations spend to build a digital Information Security Management System (ISMS) and Compliance Management System (CMS). DataGuard empowers organisations active in 50+ countries to better understand, identify, and manage the risks that matter most to them – and to build up a robust security and compliance posture that allows them to stay ahead of their evolving business and regulatory needs.
About DPOrganizer
DPOrganizer is a market leading provider of privacy management software that helps privacy professionals in 20+ countries to build more effective and sustainable data protection programs. The company offers an intuitive and easy to use software supporting customers with data mapping, assessment automation, reporting and visualization, data protection trainings, data subject request and incident management.
TISAX® is a registered trademark of the ENX Association. DataGuard is not affiliated with the ENX Association.
We provide Software-as-a-Service and support for the assessment on TISAX® only.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240605633259/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom